J&J Taking The Long View With Its Therapeutic Franchises
This article was originally published in The Pink Sheet Daily
The Big Pharma has only recently entered the diabetes drug market, but has plans to make a significant impact on how the disease is treated. During a meeting with analysts, J&J highlighted the deals it’s made and the multiple indications it will pursue within the metabolic space.
You may also be interested in...
Although still early after launch, Celltrion is battling J&J in the Korean market with a biosimilar of Remicade. If the war of words is any indication, things are just starting to heat up.
J&J received approval to market a second TNF inhibitor to treat the bowel disorder. The authorization comes as Simponi’s increasing sales point toward blockbuster status.
If approved in Europe this year, as expected, Celltrion/Hospira’s biosimilar infliximab will provide a compelling test of whether and how quickly budgetary pressures can override physician caution. It will also set the stage for the $70 billion worth of copycat antibodies in development.